Wedbush restated their neutral rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO) in a research report report published on Friday, May 5th. They currently have a $24.00 target price on the biopharmaceutical company’s stock.
Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Juno Therapeutics from a buy rating to a hold rating in a research note on Tuesday, May 2nd. FBR & Co reduced their target price on Juno Therapeutics from $30.00 to $29.00 and set a mkt perform rating on the stock in a research note on Friday, May 5th. Vetr lowered shares of Juno Therapeutics from a strong-buy rating to a buy rating and set a $25.42 price target for the company. in a research report on Monday, March 13th. JPMorgan Chase & Co. restated a neutral rating and set a $31.00 price target (down from $34.00) on shares of Juno Therapeutics in a research report on Friday, March 3rd. Finally, Maxim Group set a $34.00 price target on shares of Juno Therapeutics and gave the company a buy rating in a research report on Thursday, March 2nd. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Juno Therapeutics presently has a consensus rating of Buy and a consensus price target of $32.56.
Shares of Juno Therapeutics (NASDAQ:JUNO) traded down 1.20% during trading on Friday, reaching $24.70. The company had a trading volume of 461,334 shares. Juno Therapeutics has a 52-week low of $17.52 and a 52-week high of $49.72. The firm’s market capitalization is $2.57 billion. The company has a 50 day moving average of $24.12 and a 200-day moving average of $22.56.
Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.70) by $0.01. The firm had revenue of $19.30 million during the quarter, compared to the consensus estimate of $16 million. Juno Therapeutics had a negative net margin of 445.86% and a negative return on equity of 22.10%. The firm’s revenue was up 96.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.78) EPS. Equities analysts expect that Juno Therapeutics will post ($3.04) earnings per share for the current year.
WARNING: “Juno Therapeutics’ (JUNO) “Neutral” Rating Reaffirmed at Wedbush” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/05/19/wedbush-reiterates-neutral-rating-for-juno-therapeutics-inc-juno-updated.html.
In related news, Director Anthony B. Evnin acquired 8,000 shares of the stock in a transaction on Friday, March 10th. The stock was acquired at an average cost of $22.11 per share, for a total transaction of $176,880.00. Following the completion of the acquisition, the director now directly owns 56,990 shares of the company’s stock, valued at approximately $1,260,048.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 15.26% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System increased its position in shares of Juno Therapeutics by 0.9% in the third quarter. California State Teachers Retirement System now owns 134,405 shares of the biopharmaceutical company’s stock worth $4,033,000 after buying an additional 1,200 shares in the last quarter. Advisor Group Inc. increased its position in shares of Juno Therapeutics by 51.4% in the third quarter. Advisor Group Inc. now owns 3,815 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,296 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Juno Therapeutics by 560.7% in the third quarter. SG Americas Securities LLC now owns 26,282 shares of the biopharmaceutical company’s stock worth $789,000 after buying an additional 22,304 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Juno Therapeutics by 5.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,757,750 shares of the biopharmaceutical company’s stock worth $52,750,000 after buying an additional 94,570 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Juno Therapeutics during the third quarter worth $651,000. 61.80% of the stock is owned by institutional investors and hedge funds.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.